When Parents Decline the Vitamin K Shot: What Every Pharmacist Needs to Know

Vitamin K given shortly after birth is one of the most effective ways to prevent vitamin K deficiency bleeding (VKDB) in newborns. Since intramuscular (IM) vitamin K prophylaxis became routine, rates of late VKDB have dropped dramatically. This intervention has prevented serious complications, including intracranial hemorrhage, permanent neurologic injury, and death.¹

Still, some choose to decline the injection. Despite decades of safety and efficacy data, there have concerns regarding the ingredients in the product, pain associated with an injection, a desire to avoid what might be considered unnecessary medical intervention, or information online.

The American Academy of Pediatrics (AAP) continues to recommend a single IM dose of vitamin K for all newborns.² At the same time, health care professionals are increasingly encountering parents who ask whether vitamin K can be administered orally instead. This is an area where pharmacists can make an important contribution. Pharmacists can explain the evidence, address specific concerns, and help families understand what is known—and what is not known—about oral vitamin K.

Why Intramuscular Vitamin K Remains the Standard

Newborns enter the world with relatively low vitamin K stores. There is limited transfer of vitamin K across the placenta, breast milk contains only small amounts, and the newborn intestinal microbiome has not yet developed enough to contribute significantly to vitamin K production. As a result, infants are vulnerable to VKDB during the first several months of life. VKDB is generally classified as early, classic, or late depending on when the bleeding occurs. Late VKDB—which occurs from about 2 weeks to 6 months of age—is particularly concerning because intracranial bleeding is common among affected infants.³

Even more concerning, these infants can appear completely healthy before the bleeding occurs. Evidence from observational studies has shown that IM prophylaxis reduces the risk of late VKDB by more than 95%, supporting its continued use as the preferred approach by major professional organizations.⁴

Why Do Some Parents Decline the Injection?

It is important not to assume that those who decline vitamin K are opposed to bleeding prevention. In many cases, the decision comes from a specific concern that has not been adequately addressed. Parents or caregivers may question preservatives or other inactive ingredients, worry about causing pain during the first hours of life, or prefer a more “natural” approach to newborn care. Others may have encountered older, outdated information about a possible association between vitamin K and childhood cancer. Some may have seen claims on social media that conflict with current medical evidence.

Understanding where the concern comes from can make the conversation between parents and health care professionals much more productive. Asking what concerns them most gives the pharmacist an opportunity to address the issue directly and without judgment. The goal is not simply to convince a parent to accept an injection. The goal is to make sure the parent understands the risks and benefits well enough to make an informed decision.

Where Does Oral Vitamin K Fit?

Oral vitamin K is used in some countries when parents decline IM prophylaxis; however, it is not a straightforward substitute for the injection. Currently in the United States, there is no oral vitamin K product approved specifically for routine neonatal VKDB prophylaxis. In addition, oral regimens require multiple doses over an extended period of time rather than a single dose prior to discharge from the hospital. That creates a practical problem, because every additional dose is another opportunity for a dose to be missed.

Studies have found that multidose oral regimens are better than providing no prophylaxis, but they have not consistently demonstrated the same level of protection as IM vitamin K.⁵ This distinction is particularly important for infants either who are exclusively breastfed or those with unrecognized cholestatic liver disease, because absorption of orally administered vitamin K may be impaired.

Oral vitamin K should not be described to parents as being equivalent to IM prophylaxis. Although oral vitamin K can be effective when every dose is administered correctly, IM prophylaxis is more reliable because protection is achieved with a single administration prior to hospital discharge.⁶ However, when a family continues to decline the injection after appropriate counseling, an oral regimen may be considered a harm-reduction approach in settings where an appropriate regimen and follow-up are available. It is crucial that families understand that this approach requires strict adherence and does not provide the same level of protection as IM administration.

The Pharmacist’s Role in Shared Decision-Making

Pharmacists are well positioned to help families navigate questions about vitamin K because they can translate medication-related evidence into practical, more accessible information for parents. The first step is to understand the family’s concerns. Most parents who ask about vitamin K are trying to make what they believe is the safest choice for their baby. Acknowledging that goal can help establish trust and make the conversation less adversarial.

It is also important to explain the difference between efficacy and real-world effectiveness. An oral regimen may work when every dose is administered correctly, but IM vitamin K is more reliable in practice because the entire prophylactic dose is administered at once. There is no need for parents to remember additional doses after leaving the hospital. The practical differences should also be discussed. Depending on the institution and location, obtaining an appropriate oral formulation may also be difficult.

Finally, pharmacists should document the counseling provided and communicate it with the rest of the health care team. Pediatricians, obstetric providers, nurses, and pharmacists should ideally provide consistent information about the benefits and limitations of each approach.

Developing Institutional Protocols

As more families ask about alternatives to IM vitamin K, hospitals may benefit from having a standardized process for responding to refusals. Without a consistent approach, counseling can vary considerably depending on which health care professional speaks with the family. Pharmacists can help develop these protocols by reviewing the current evidence and professional recommendations, assisting with dosing and formulation considerations when an oral regimen is used, and developing standardized educational materials for families. They can also educate other members of the health care team about the differences between IM and oral prophylaxis.

In addition, pharmacy involvement in quality improvement efforts could help institutions track vitamin K refusal rates, identify common parental concerns, and evaluate whether educational interventions affect acceptance. A standardized process does not mean every family needs to receive the same conversation. Instead, it provides clinicians with a consistent foundation while still allowing counseling to be tailored to individual concerns.

Looking Ahead

Parental refusal of IM vitamin K is unlikely to be solved simply by providing more information. How that information is presented matters. Parents may be more receptive when clinicians take time to understand their concerns rather than immediately dismissing them. This creates an opportunity for pharmacists to play a larger role in newborn care. Pharmacists can help families distinguish evidence-based concerns from outdated or inaccurate information while still respecting the parent's role in making decisions for their child. When IM vitamin K is declined, pharmacists can also help minimize potential harm by making sure families understand the limitations of oral prophylaxis, the importance of following the complete dosing regimen when one is recommended, and the signs of VKDB that require immediate medical attention.

Conclusion

Interest in oral vitamin K is part of a larger shift toward shared decision-making and greater parental involvement in newborn care. Although IM vitamin K remains the preferred and most effective method of preventing VKDB, pharmacists have an important role when parents have questions or ultimately decline the injection.

The pharmacist’s role is more than providing a medication recommendation. It is also to listen, explain the evidence in understandable terms, correct misconceptions, and help families understand the consequences of the available choices. When IM prophylaxis is refused, thoughtful counseling and a consistent institutional approach can help reduce preventable harm while maintaining trust between families and their health care team.

REFERENCES

1. Committee on Fetus and Newborn. Controversies Concerning Vitamin K and the Newborn. Pediatrics. 2003;112(1):191–192. doi:10.1542/peds.112.1.191

2. Cheng JH, Loyal J, Wood KE, Kair LR. Oral Vitamin K Prophylaxis in Newborns: A Survey of Clinician Opinions and Practices. Hosp Pediatr. 2020;10(2):153-158. doi:10.1542/hpeds.2019-0219

3. Shearer MJ. Vitamin K deficiency bleeding (VKDB) in early infancy. Blood Rev. 2009;23(2):49-59.doi:10.1016/j.blre.2008.06.001

4. Sankar MJ, Chandrasekaran A, Kumar P, Thukral A, Agarwal R, Paul VK. Vitamin K prophylaxis for prevention of vitamin K deficiency bleeding: a systematic review. J Perinatol. 2016;36 Suppl 1(Suppl 1):S29-S35. doi:10.1038/jp.2016.30

5. Mirone A, Mannino D, Leonardi R, et al. Vitamin K Prophylaxis in Newborns: A Narrative Review of the Molecular Basis, Clinical Evidence, and Comparative Effectiveness of Intramuscular Versus Oral Administration and Parental Hesitation. Int J Mol Sci. 2026;27(4):1669. doi:10.3390/ijms27041669

6. Jullien S. Vitamin K prophylaxis in newborns. BMC Pediatr. 2021;21(Suppl 1):350. Published 2021 Sep 8. doi:10.1186/s12887-021-02701-4